LIPOCINE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.04 USD | +5.04% |
|
+13.53% | +116.49% |
| May. 09 | Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M | MT |
| May. 09 | Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechWing Yip (Analysts)[Audio Gap] metabolic and endocrine disorders. Dr. Patel, D...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Calendar
2024-06-05
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.04
USD
Average target price
33.19
USD
Spread / Average Target
+449.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +116.49% | 32.3M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.65% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- LPCN Stock
- News Lipocine Inc.
- Transcript : Lipocine Inc. Presents at H.C. Wainwright 5th Annual NASH Investor Conference, Oct-12-2021 03
